Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Rhea-AI Summary

Black Diamond Therapeutics (Nasdaq: BDTX) will host a live webcast on Wednesday, December 3, 2025 at 8:00am ET to present results from its Phase 2 clinical trial of silevertinib and to provide a program update.

Investors can access the webcast under “Events and Presentations” in the Investors section at www.blackdiamondtherapeutics.com. A replay will be available after the event.

Webcast to be held Wednesday, December 3, at 8:00am ET

CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, will host a webcast to present results from its Phase 2 clinical trial of silevertinib and provide a program update on Wednesday, December 3, 2025, at 8:00am ET.

Webcast information

The webcast can be accessed under “Events and Presentations” on the Investors section of the Black Diamond website at www.blackdiamondtherapeutics.com. A replay of the webcast will be available following the completion of the event.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 non-small cell lung cancer (NSCLC) trial of silevertinib, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.

From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this press release.

Contact

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com

FAQ

When will Black Diamond Therapeutics (BDTX) present Phase 2 silevertinib results?

The webcast is scheduled for December 3, 2025 at 8:00am ET.

How can investors access the BDTX webcast for silevertinib results on December 3, 2025?

Access the webcast via Events and Presentations in the Investors section at www.blackdiamondtherapeutics.com.

Will a replay of the BDTX December 3, 2025 webcast be available?

Yes. A replay will be available following completion of the event.

What will Black Diamond cover in the December 3, 2025 webcast about silevertinib?

The company will present Phase 2 clinical trial results for silevertinib and provide a program update.

Is the December 3, 2025 BDTX presentation focused on clinical data or corporate strategy?

The presentation is focused on Phase 2 clinical trial results for silevertinib and an accompanying program update.